NASDAQ:MGTX MeiraGTx (MGTX) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free MGTX Stock Alerts $4.71 -0.15 (-3.09%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$4.68▼$4.8150-Day Range$4.71▼$6.5252-Week Range$3.49▼$8.35Volume121,649 shsAverage Volume150,163 shsMarket Capitalization$302.48 millionP/E RatioN/ADividend YieldN/APrice Target$25.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get MeiraGTx alerts: Email Address MeiraGTx MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside444.9% Upside$25.67 Price TargetShort InterestHealthy1.78% of Shares Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.48Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.40) to $0.90 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector220th out of 908 stocksBiological Products, Except Diagnostic Industry22nd out of 151 stocks 3.5 Analyst's Opinion Consensus RatingMeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMeiraGTx has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.78% of the outstanding shares of MeiraGTx have been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in MeiraGTx has recently decreased by 0.87%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMeiraGTx does not currently pay a dividend.Dividend GrowthMeiraGTx does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMeiraGTx has received a 78.28% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for MeiraGTx is -0.54. Previous Next 1.9 News and Social Media Coverage News SentimentMeiraGTx has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MeiraGTx this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MeiraGTx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.70% of the stock of MeiraGTx is held by insiders.Percentage Held by Institutions67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MeiraGTx are expected to grow in the coming year, from ($1.40) to $0.90 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MeiraGTx is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MeiraGTx is -3.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMeiraGTx has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About MeiraGTx Stock (NASDAQ:MGTX)MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Read More MGTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGTX Stock News HeadlinesApril 25, 2024 | finance.yahoo.comMeiraGTx Holdings plc (NASDAQ:MGTX): Is Breakeven Near?April 24, 2024 | globenewswire.comMeiraGTx to Participate in Upcoming Investor ConferencesApril 26, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 18, 2024 | globenewswire.comMeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual ConferenceMarch 17, 2024 | finance.yahoo.comMGTX Apr 2024 12.500 callMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed: Meiragtx Holdings’ Promising Pipeline and Strategic Partnerships Set Stage for GrowthMarch 14, 2024 | investorplace.comMGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comRecap: MeiraGTx Hldgs Q4 EarningsApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 14, 2024 | hk.finance.yahoo.comMeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023March 14, 2024 | baystreet.caMeira Retreats on Financial FiguresMarch 14, 2024 | globenewswire.comMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business UpdatesFebruary 26, 2024 | finance.yahoo.comMeiraGTx Holdings plc (NASDAQ:MGTX) stock most popular amongst private equity firms who own 28%, while individual investors hold 26%February 17, 2024 | finance.yahoo.comMGTX Mar 2024 12.500 callFebruary 16, 2024 | seekingalpha.comMeiraGTx: Bota-Vec Program Advancing With Milestones Being MetFebruary 15, 2024 | morningstar.comMeiraGTx Holdings PLC MGTXFebruary 13, 2024 | finance.yahoo.comMeiraGTx Announces $50 Million Milestone from Janssen PharmaceuticalsJanuary 10, 2024 | finance.yahoo.comWall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a BetJanuary 10, 2024 | finance.yahoo.comMeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate RevisionsDecember 25, 2023 | finance.yahoo.comWall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to TradeDecember 24, 2023 | benzinga.comMeiraGTx Hldgs Stock (NASDAQ:MGTX), Short Interest ReportDecember 23, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)December 22, 2023 | benzinga.comMeiraGTx Hldgs Stock (NASDAQ:MGTX) Dividends: History, Yield and DatesDecember 21, 2023 | marketwatch.comMeiraGTx Shares Rise 20% After Asset Purchase Deal With Janssen PharmaDecember 21, 2023 | msn.comMeiraGTx signs asset purchase agreement for bota-vec collaboration with JanssenDecember 21, 2023 | msn.comWhy Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?December 21, 2023 | finance.yahoo.comMeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 millionSee More Headlines Receive MGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/25/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MGTX CUSIPN/A CIK1735438 Webwww.meiragtx.com Phone(646) 860-7985FaxN/AEmployees419Year FoundedN/APrice Target and Rating Average Stock Price Target$25.67 High Stock Price Target$41.00 Low Stock Price Target$11.00 Potential Upside/Downside+444.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-84,030,000.00 Net Margins-599.47% Pretax Margin-599.47% Return on Equity-114.33% Return on Assets-42.56% Debt Debt-to-Equity Ratio0.62 Current Ratio2.38 Quick Ratio2.38 Sales & Book Value Annual Sales$14.02 million Price / Sales21.58 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book2.17Miscellaneous Outstanding Shares64,217,000Free Float57,988,000Market Cap$302.46 million OptionableOptionable Beta1.29 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Alexandria Forbes Ph.D. (Age 59)CEO, President & Director Comp: $2.33MMr. Richard Brian Giroux B.A. (Age 51)COO & CFO Comp: $1.83MDr. Stuart Naylor Ph.D. (Age 61)Chief Development Officer Comp: $1MMr. Robert J. Wollin J.D. (Age 48)General Counsel & Secretary Dr. Michel Michaelides M.D.Head of Clinical OphthalmologyMs. Christine Elise Sheehy (Age 56)Senior Vice President of Global Integration Mr. Tim RandallSenior Vice President of Risk & Internal ControlsDr. Alastair Leighton Ph.D.Senior Vice President of Manufacturing & Supply ChainDr. Robert K. Zeldin M.D. (Age 61)Chief Medical Officer Comp: $1.1MMore ExecutivesKey CompetitorsOcugenNASDAQ:OCGNSOPHiA GENETICSNASDAQ:SOPHAnavex Life SciencesNASDAQ:AVXLJasper TherapeuticsNASDAQ:JSPRSolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsLos Angeles Capital Management LLCBought 116,303 shares on 4/5/2024Ownership: 0.181%Sierra Summit Advisors LLCBought 35,884 shares on 2/22/2024Ownership: 0.056%Rhenman & Partners Asset Management ABSold 506,895 shares on 2/13/2024Ownership: 0.050%Tower Research Capital LLC TRC Bought 2,045 shares on 2/13/2024Ownership: 0.007%Letko Brosseau & Associates Inc.Bought 10,000 shares on 2/12/2024Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions MGTX Stock Analysis - Frequently Asked Questions Should I buy or sell MeiraGTx stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGTX shares. View MGTX analyst ratings or view top-rated stocks. What is MeiraGTx's stock price target for 2024? 2 equities research analysts have issued 1 year target prices for MeiraGTx's stock. Their MGTX share price targets range from $11.00 to $41.00. On average, they predict the company's stock price to reach $25.67 in the next twelve months. This suggests a possible upside of 444.9% from the stock's current price. View analysts price targets for MGTX or view top-rated stocks among Wall Street analysts. How have MGTX shares performed in 2024? MeiraGTx's stock was trading at $7.02 at the beginning of the year. Since then, MGTX stock has decreased by 32.9% and is now trading at $4.71. View the best growth stocks for 2024 here. When is MeiraGTx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MGTX earnings forecast. How were MeiraGTx's earnings last quarter? MeiraGTx Holdings plc (NASDAQ:MGTX) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.01. The firm had revenue of $2.04 million for the quarter, compared to the consensus estimate of $10.13 million. MeiraGTx had a negative net margin of 599.47% and a negative trailing twelve-month return on equity of 114.33%. What other stocks do shareholders of MeiraGTx own? Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD). When did MeiraGTx IPO? MeiraGTx (MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager. Who are MeiraGTx's major shareholders? MeiraGTx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Alexandria Forbes, Elizabeth A Cook, Perceptive Advisors Llc, Richard Giroux, Robert J Wollin, Robert K Zeldin and Stuart Naylor. View institutional ownership trends. How do I buy shares of MeiraGTx? Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
